https://doi.org/10.55788/2d6cb85a
The phase 3 IFM2017-03 trial (NCT03993912) randomised 295 frail patients (based on ECOG proxy frailty assessment) of at least 65 years of age with newly diagnosed MM 2:1 to daratumumab plus lenalidomide or lenalidomide plus dexamethasone [1]. The primary endpoint of the trial was PFS.
After a median follow-up of 46.3 months, the daratumumab group outperformed the dexamethasone group in terms of median PFS (53.4 vs 22.5 months; HR 0.51; 95% CI 0.37–0.70; P<0.0001). “This represents a 49% reduction in the risk of progression or death for participants on daratumumab,” said Prof. Salomon Manier (University of Lille, France). Similarly, the median overall survival was significantly longer in the daratumumab group than in the dexamethasone group (not reached vs 47.2 months; HR 0.52; 95% CI 0.35–0.77; P=0.0001).
Grade 3 or higher neutropenia (55% vs 24%), anaemia (12% vs 3%), and thrombocytopenia (10% vs 5%) were more frequently observed in the daratumumab arm. “There were no differences between the study arms concerning infections or treatment discontinuations,” added Prof. Manier.
“The phase 3 IFM2017-03 trial demonstrated that a dexamethasone-sparing strategy is efficacious and safe for the treatment of frail patients with previously untreated MM,” decided Prof. Manier.
- Manier S, et al. A dexamethasone sparing regimen with daratumumab and lenalidomide in frail patients with newly diagnosed multiple myeloma: the phase 3 IFM2017-03 trial. Abstract 774, 66th ASH Annual Meeting, 7–10 December 2024, San Diego, CA, USA.
Copyright ©2025 Medicom Medical Publishers
Posted on
Previous Article
« CEPHEUS: Further support for daratumumab regimens in untreated MM Next Article
Emerging mezigdomide-based options for heavily pre-treated MM »
« CEPHEUS: Further support for daratumumab regimens in untreated MM Next Article
Emerging mezigdomide-based options for heavily pre-treated MM »
Table of Contents: ASH 2024
Featured articles
Meet the Trialist: Prof. Mats Jerkeman on the ALTAMIRA trial
Lymphoma
InMIND: Novel standard-of-care for relapsed or refractory follicular lymphoma?
High CR rates for novel CAR T-cell therapy in follicular lymphoma and DLBCL
Excellent CR rates for venetoclax plus pola-R-CHP in BCL2-positive DLBCL
ATALANTA-1: Promising data for novel CAR T-cell therapy
ZUMA-5: Curative potential of axi-cel in follicular lymphoma
Can we omit auto-SCT in patients with mantle cell lymphoma with undetectable MRD post-induction?
Leukaemia
Quizartinib maintenance therapy crucial for FLT3-ITD-positive AML
Revumenib combination therapy associated with high response rates in relapsed/refractory AML
Venetoclax plus azacitidine in young patients with AML
Promising results for ivosidenib-based triplet therapy in IDH1-mutated malignancies
CPX-351 outperforms FLAG-Ida in AML/MDS and MDS-related mutations
High MRD-negativity rates for venetoclax plus ‘7+3’ chemotherapy in newly diagnosed AML
Findings from phase 3 uproleselan study in AML not all negative
Menin inhibitors on the rise in KMT2Ar acute leukaemia
New standard-of-care for paediatric B-cell ALL
Multiple Myeloma
KCRd offers overall survival benefit over CRd in newly diagnosed MM
AQUILA: Early intervention with daratumumab extends survival in smouldering MM
Emerging mezigdomide-based options for heavily pre-treated MM
IFM2017-03: Daratumumab therapy fruitful for frail patients with MM
CEPHEUS: Further support for daratumumab regimens in untreated MM
Non-Malignant Haematology
Positive trends for etavopivat in sickle cell disease
LUNA 3: Rilzabrutinib meets primary endpoint in ITP
Full-dose or reduced-dose DOACs in high-risk VTE on extended therapy?
Allo-SCT improves lives of children with sickle cell anaemia and abnormal cerebral artery velocities
PIVOT: Can hydroxyurea improve outcomes in haemoglobin sickle cell disease?
Miscellaneous
ANDROMEDA: Daratumumab-based frontline standard-of-care in AL amyloidosis
Related Articles
October 4, 2021
Pandemic tied to drop in colorectal-cancer diagnoses
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com